Fresenius Kabi
Products for chronically and critically ill patients
Fresenius Helios
Europe’s leading private healthcare provider
Archive "Stories"
Contact
Nick Stone Senior Vice President Investor Relations Head of Investor Relations
ir-fre@fresenius.com
Anke Schmidt Chief Communications Officer T +49 (0) 6172 686 495
anke.schmidt@fresenius.com
Share
Facebook
Twitter
LinkedIn
Xing
E-Mail
Services
Print
RSS
September 11, 2015
Moxifloxacin injection further expands the Fresenius Kabi anti-infective portfolio. It is available in the company's proprietary Freeflex® bag.